NNVC vs. TRAW, RDHL, MIRA, IMNN, PPBT, KPRX, EDSA, TNXP, MNPR, and ELAB
Should you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Traws Pharma (TRAW), RedHill Biopharma (RDHL), MIRA Pharmaceuticals (MIRA), Imunon (IMNN), Purple Biotech (PPBT), Kiora Pharmaceuticals (KPRX), Edesa Biotech (EDSA), Tonix Pharmaceuticals (TNXP), Monopar Therapeutics (MNPR), and Elevai Labs (ELAB). These companies are all part of the "pharmaceutical preparations" industry.
NanoViricides (NYSE:NNVC) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
NanoViricides and Traws Pharma both received 0 outperform votes by MarketBeat users.
NanoViricides has a net margin of 0.00% compared to Traws Pharma's net margin of -8,384.07%. NanoViricides' return on equity of -63.97% beat Traws Pharma's return on equity.
In the previous week, NanoViricides had 1 more articles in the media than Traws Pharma. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Traws Pharma. NanoViricides' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.
NanoViricides has higher earnings, but lower revenue than Traws Pharma. NanoViricides is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.
10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 4.6% of NanoViricides shares are owned by insiders. Comparatively, 3.3% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
NanoViricides has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.
Summary
NanoViricides beats Traws Pharma on 8 of the 11 factors compared between the two stocks.
Get NanoViricides News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NanoViricides Competitors List
Related Companies and Tools
